Cyclopharm Secures 11-Site US Technegas Deployment with UH Cleveland

Cyclopharm (ASX:CYC) has signed an agreement to install Technegas across 11 clinical locations operated by University Hospitals (UH) in Cleveland, Ohio.

All 11 systems are scheduled for installation over the next few weeks after UH completed the required site preparation work before signing the agreement.

The immediate system-wide rollout establishes Cyclopharm across northern Ohio and expands its presence among major US academic health systems and integrated health delivery networks.

Each installed site is expected to generate recurring revenue from per-patient functional ventilation imaging procedures, with consumables and service revenue scaling alongside procedure volumes.

Cyclopharm considers the deployment a validation of its enterprise-wide adoption model, which forms a key part of its US growth strategy.

Academic Health System Reach

Founded in 1866, UH serves more than one million patients annually across northern Ohio and employs more than 32,000 caregivers.

Its network is anchored by University Hospitals Cleveland Medical Center (UHC), a medical complex with more than 1,000 beds that is the primary teaching hospital of Case Western Reserve University School of Medicine.

UHC has appeared on the US News & World Report Best Hospitals list for 27 consecutive years, while its researchers led more than 3,400 active clinical trials and published nearly 1,500 peer-reviewed articles in 2024.

The network includes nationally recognised centres such as UH Seidman Cancer Center and UH Rainbow Babies & Children’s Hospital, which was ranked among the top 50 US children’s hospitals across all 11 paediatric specialties in the 2025–26 US News rankings.

Cyclopharm expects UH to become a national reference site that can demonstrate enterprise-scale Technegas adoption to other institutions and support broader clinical uptake.

Platform Supports Broader Research

Technegas is a structured ultra-fine dispersion of radioactively labelled carbon used for functional lung ventilation imaging.

In the US, the product is indicated for visualising pulmonary ventilation and evaluating pulmonary embolism when paired with perfusion imaging in adults and paediatric patients aged six years and older.

Cyclopharm highlighted a growing body of clinical research into other respiratory conditions, including chronic obstructive pulmonary disease, asthma, and pulmonary hypertension, as well as interventional lung procedures.

Those additional applications remain under investigation and are not currently approved indications in the US.

Immediate Network-Wide Rollout

The agreement differs from staged multi-site deployments because every Technegas installation is planned within the same near-term rollout window.

“What makes this agreement particularly significant is its immediacy,” chief executive officer James McBrayer said.

“Rather than a staged rollout over time, UH has elected to install Technegas system-wide, at 11 locations over the next few weeks, deepening our recurring revenue base and reflecting the confidence UH has placed in Technegas at enterprise scale.”

“Its distinctive characteristics, in particular its ultra-fine particle dispersion and uniform lung distribution, make it well-suited as a platform for the next generation of quantitative and AI-driven lung imaging where the ability to deliver true functional measurement of the lung complements the structural information provided by other imaging modalities.”

“Partnering with a research institution of University Hospitals’ calibre positions Technegas at the forefront of these developments.”